News Home Page
Recent News
In Depth
Trends + Issues
News Elsewhere
Business Optimism Increasing in Minnesota
Leadership Home Page
Corporate Responsibility
Economic Development
Education
Leaders
Managing
Public Policy
For Pro Soccer in MN, Is It Now or Never?
Industries Home Page
Accounting
Banking + Finance
Capital Markets
Education + Training
Energy
Food
Health Care
Human Capital
Insurance
Law
Life Sciences
Manufacturing
Marketing, Advertising, PR and Media
Nonprofits and the Arts
Real Estate
Retail + Hospitality
Technology
Telecommunications
Transportation
Polaris Is Trailblazing Again, This Time Overseas
Lists + Research Home Page
B.I.G. Book of Business Lists
Lists
Research
Opinion Home Page
Blogs
Columns
Life Style Home Page
Concierge
Off the Clock
Personal Brand
Plugged In
Honors + Events Home Page
Upcoming Events
Entrepreneurs of the Year
Minnesota Business Hall of Fame
Minnesota Cup
Minnesota Family Business Awards
Minnesotans You Should Know
Outstanding Directors Awards
Small Business Success Stories
Smart Solutions
Current Issue
Archives
Subscribe
Some of the company’s products that are used in catheterization procedures have been recalled because of a potential for air leakage, which could lead to an obstructed artery and result in serious injury or death.
Longtime CEO Thomas Oland resigned in November and said he disagreed with the board’s decision to consider external candidates for his successor; now, the board has tapped an outsider as its next leader.
Sales also declined in the cardiac rhythm disease management and spinal products businesses, two of the company’s largest and highest-margin segments.
The recently released figure gives the first and only indication to date about how the Natick, Massachusetts-based company’s ongoing restructuring is affecting its local work force.
The financing round, led by the Malaysian government, will help Mardil Medical complete the development of its first product and pursue regulatory approval in Europe, Asia, and Canada.
Greg Fluet, who has served as interim CEO since November, takes the helm at a time when the company’s stock is struggling to meet Nasdaq’s minimum bid price requirements.
Designs on your genes.
Boston Scientific said Tuesday that its fourth-quarter earnings fell 44 percent—and that it will eliminate 900 to 1,000 positions this year in addition to previously announced cuts.
The state is poised to become the place where diabetes is cured.
The company previously said it expected to receive such a letter from regulators following the inspection of a manufacturing facility in California.
Target Field Legends Club - Carew Atrium June 06, 2013
Minnesota Landscape Arboretum June 07, 2013
• See All Life Sciences Events
Read this month's issue of Twin Cities Business.
Digital Edition Sponsored by